Sonnet BioTherapeutics Holdings Overview
Valuation check: SONN's P/E ratio is -0.53, below the Consumer Staples sector average of 22.76.
Get informed when a big investor buys or sells
+ Follow-0.53
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for SONN is -0.53. That is below the Consumer Staples sector average of 22.76. Investors often review this figure alongside Sonnet BioTherapeutics Holdings's historical trend and sector peers before judging valuation or financial health.
Against Consumer Staples companies, SONN currently prints -0.53 for P/E ratio, while the sector average sits near 22.76. That is roughly 102.3% below the sector mean. Large gaps often invite a closer look at Sonnet BioTherapeutics Holdings's growth, margins, and balance sheet.
A P/E ratio of -0.53 for Sonnet BioTherapeutics Holdings is not 'good' or 'bad' on its own. Compare it with the peer average (22.76) and with SONN's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting SONN's P/E ratio (-0.53), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Sonnet BioTherapeutics Holdings's P/E ratio against similar Consumer Staples names. You can also browse sector and industry screens on Stockcircle for a broader set of Consumer Staples companies and their key multiples and fundamentals.
